Market Overview:
The global HIV associated lipodystrophy syndrome treatment market is expected to grow at a CAGR of 7.5% from 2018 to 2030. The market growth can be attributed to the increasing prevalence of HIV, growing awareness about HIV associated lipodystrophy syndrome (HALS), and technological advancements in the field of HALS treatment. The specific drug treatment segment is expected to dominate the global HALS treatment market during the forecast period owing to the availability of a large number of drugs for treating HALS and their high efficacy rates. However, cosmetic corrective treatments are also gaining popularity due to their ability to improve appearance and quality of life in patients with HALS. S., Canada, and Mexico.
Product Definition:
HIV Associated Lipodystrophy Syndrome Treatment is the treatment for HIV associated lipodystrophy syndrome. This syndrome is a condition that causes changes in the way a person's body looks. People with this syndrome may have too much fat on their stomach, arms, and legs, or they may lose fat from these areas. They may also have problems with their cholesterol levels and blood sugar levels.
Specific Drug Treatment:
Specific drug treatment, it's usage.
ABSTRACT Introduction of new drugs for the treatment of HIV associated lipodystrophy syndrome is one of the major factors driving growth in this sector. The introduction of novel drugs with different mechanisms of actions has been a major driver for progress over the past few years.
Cosmetic Corrective Treatment:
Cosmetic corrective treatment is a cosmetic procedure that aims to improve the appearance of damaged or disfiguring skin. It includes procedures such as scar revision, acne reduction, and skin tightening. Cosmetic corrective treatments are generally performed by dermatologists but can also be done by certified esthetic professionals under training.
Application Insights:
Based on application, the market is segmented into hospital, specialized clinic and others. Hospital was estimated as the largest revenue generating center in 2017 owing to its wide usage for the treatment of HIV associated lipodystrophy syndrome. It has been observed that patients diagnosed with HIV associated lipodystrophy syndrome are hospitalized due to severe symptoms of weight loss and muscle wasting. This trend is expected to continue over the forecast period due primarily to rising cases of AIDS across various regions coupled with growing awareness about this condition among general practitioners and specialists in clinics worldwide.
HIV-associated lipodystrophy syndrome has been reported most commonly among homosexual males who have sex with men (MSM) globally; however, it can affect people of any sexual orientation or gender identity (GID).
Regional Analysis:
North America dominated the global HIV-associated lipodystrophy syndrome treatment market in 2017. This can be attributed to the presence of key players, availability of effective drugs, high healthcare expenditure and awareness campaigns regarding available treatments for obesity. Moreover, increasing cases of obesity among adults are driving growth in this region. According to CDC statistics published in 2016, more than 30% population aged 20 years and above was obese that year.
Asia Pacific is expected to witness lucrative growth over the forecast period owing to rising disposable income leading to improved access to health care facilities along with growing awareness about various treatment options for HIV associated lipodystrophy syndrome & related disorders amongst patients as well as physicians. Furthermore, a large number of patients from China and India have been traveling overseas for medical reasons such as weight loss surgery resulting into an increase in demand for these procedures across this region during the forecast period (2018 - 2030).
Growth Factors:
- Increasing incidence of HIV-associated lipodystrophy syndrome (HALS)
- Growing awareness about HALS and its treatment options
- Rising demand for better and more effective treatments for HALS
- Availability of government funding for research on HALS treatments
- Technological advancements in the field of lipodystrophy syndrome treatment
Scope Of The Report
Report Attributes
Report Details
Report Title
HIV Associated Lipodystrophy Syndrome Treatment Market Research Report
By Type
Specific Drug Treatment, Cosmetic Corrective Treatment
By Application
Hospital, Specialist Clinic, Others
By Companies
Gilead Sciences, Amgen, Abbott, AstraZeneca, AbbVie, GlaxoSmithKline, Alfa Wassermann SPA, Theratechnologies, Bristol-Myers Squibb
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
156
Number of Tables & Figures
110
Customization Available
Yes, the report can be customized as per your need.
Global HIV Associated Lipodystrophy Syndrome Treatment Market Report Segments:
The global HIV Associated Lipodystrophy Syndrome Treatment market is segmented on the basis of:
Types
Specific Drug Treatment, Cosmetic Corrective Treatment
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Specialist Clinic, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Gilead Sciences
- Amgen
- Abbott
- AstraZeneca
- AbbVie
- GlaxoSmithKline
- Alfa Wassermann SPA
- Theratechnologies
- Bristol-Myers Squibb
Highlights of The HIV Associated Lipodystrophy Syndrome Treatment Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Specific Drug Treatment
- Cosmetic Corrective Treatment
- By Application:
- Hospital
- Specialist Clinic
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the HIV Associated Lipodystrophy Syndrome Treatment Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
There is no specific HIV Associated Lipodystrophy Syndrome treatment, but treatments for the underlying condition are typically effective. Treatment may include medications to improve blood flow and reduce inflammation, weight loss or exercise programs, and surgery to remove fat from areas of excessive accumulation.
Some of the major companies in the hiv associated lipodystrophy syndrome treatment market are Gilead Sciences, Amgen, Abbott, AstraZeneca, AbbVie, GlaxoSmithKline, Alfa Wassermann SPA, Theratechnologies, Bristol-Myers Squibb.
The hiv associated lipodystrophy syndrome treatment market is expected to register a CAGR of 7.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 HIV Associated Lipodystrophy Syndrome Treatment Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 HIV Associated Lipodystrophy Syndrome Treatment Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 HIV Associated Lipodystrophy Syndrome Treatment Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the HIV Associated Lipodystrophy Syndrome Treatment Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global HIV Associated Lipodystrophy Syndrome Treatment Market Size & Forecast, 2018-2028
4.5.1 HIV Associated Lipodystrophy Syndrome Treatment Market Size and Y-o-Y Growth
4.5.2 HIV Associated Lipodystrophy Syndrome Treatment Market Absolute $ Opportunity
Chapter 5 Global HIV Associated Lipodystrophy Syndrome Treatment Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 HIV Associated Lipodystrophy Syndrome Treatment Market Size Forecast by Type
5.2.1 Specific Drug Treatment
5.2.2 Cosmetic Corrective Treatment
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global HIV Associated Lipodystrophy Syndrome Treatment Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 HIV Associated Lipodystrophy Syndrome Treatment Market Size Forecast by Applications
6.2.1 Hospital
6.2.2 Specialist Clinic
6.2.3 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global HIV Associated Lipodystrophy Syndrome Treatment Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 HIV Associated Lipodystrophy Syndrome Treatment Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America HIV Associated Lipodystrophy Syndrome Treatment Analysis and Forecast
9.1 Introduction
9.2 North America HIV Associated Lipodystrophy Syndrome Treatment Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America HIV Associated Lipodystrophy Syndrome Treatment Market Size Forecast by Type
9.6.1 Specific Drug Treatment
9.6.2 Cosmetic Corrective Treatment
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America HIV Associated Lipodystrophy Syndrome Treatment Market Size Forecast by Applications
9.10.1 Hospital
9.10.2 Specialist Clinic
9.10.3 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe HIV Associated Lipodystrophy Syndrome Treatment Analysis and Forecast
10.1 Introduction
10.2 Europe HIV Associated Lipodystrophy Syndrome Treatment Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe HIV Associated Lipodystrophy Syndrome Treatment Market Size Forecast by Type
10.6.1 Specific Drug Treatment
10.6.2 Cosmetic Corrective Treatment
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe HIV Associated Lipodystrophy Syndrome Treatment Market Size Forecast by Applications
10.10.1 Hospital
10.10.2 Specialist Clinic
10.10.3 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific HIV Associated Lipodystrophy Syndrome Treatment Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific HIV Associated Lipodystrophy Syndrome Treatment Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific HIV Associated Lipodystrophy Syndrome Treatment Market Size Forecast by Type
11.6.1 Specific Drug Treatment
11.6.2 Cosmetic Corrective Treatment
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific HIV Associated Lipodystrophy Syndrome Treatment Market Size Forecast by Applications
11.10.1 Hospital
11.10.2 Specialist Clinic
11.10.3 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America HIV Associated Lipodystrophy Syndrome Treatment Analysis and Forecast
12.1 Introduction
12.2 Latin America HIV Associated Lipodystrophy Syndrome Treatment Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America HIV Associated Lipodystrophy Syndrome Treatment Market Size Forecast by Type
12.6.1 Specific Drug Treatment
12.6.2 Cosmetic Corrective Treatment
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America HIV Associated Lipodystrophy Syndrome Treatment Market Size Forecast by Applications
12.10.1 Hospital
12.10.2 Specialist Clinic
12.10.3 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) HIV Associated Lipodystrophy Syndrome Treatment Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) HIV Associated Lipodystrophy Syndrome Treatment Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) HIV Associated Lipodystrophy Syndrome Treatment Market Size Forecast by Type
13.6.1 Specific Drug Treatment
13.6.2 Cosmetic Corrective Treatment
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) HIV Associated Lipodystrophy Syndrome Treatment Market Size Forecast by Applications
13.10.1 Hospital
13.10.2 Specialist Clinic
13.10.3 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 HIV Associated Lipodystrophy Syndrome Treatment Market: Competitive Dashboard
14.2 Global HIV Associated Lipodystrophy Syndrome Treatment Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Gilead Sciences
14.3.2 Amgen
14.3.3 Abbott
14.3.4 AstraZeneca
14.3.5 AbbVie
14.3.6 GlaxoSmithKline
14.3.7 Alfa Wassermann SPA
14.3.8 Theratechnologies
14.3.9 Bristol-Myers Squibb
